about
TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease. The company is also evaluating Bryostatin-1 for other neurodegenerative and cognitive conditions...
Read More
5.70
-0.33
(-5.47%)
119.6K
XNAS Volume
XNAS 13 May, 2026 5:30 PM (EDT)
Board Meeting
The next board meeting for Synaptogenix Inc is on 15 May 2026 for the purpose of Synaptogenix Inc First Quarter Earnings Results for 2026
See details
Not Eligible
Expensive Valuation
Technically Neutral
Synaptogenix Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..